<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142791</url>
  </required_header>
  <id_info>
    <org_study_id>UF033</org_study_id>
    <nct_id>NCT01142791</nct_id>
  </id_info>
  <brief_title>Safety Study of ExAblate for the Treatment of Uterine Fibroids</brief_title>
  <official_title>A Phase IV Clinical Study To Evaluate the Safety of MR-Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this Phase IV study is to evaluate the safety of the ExAblate treatment of
      uterine fibroids using the enhanced sonication techniques, based on the current
      commercially-approved treatment guidelines. Treatment may include up to 100% of individual
      fibroid volume, within established serosal and sacral treatment margins.

      The Enhanced sonication is one of the various sonication modes that may lead to increased
      thermal dose volume of each sonication without additional safety risks. This is an additional
      treatment tool available in the ExAblate system for the treatment of uterine fibroids.

      The safety profile of the Enhanced Sonication was investigated under an FDA-regulated IDE
      study. FDA granted approval of Enhanced Sonication with the requirement to perform a
      post-approval study to collect additional safety data when treating up to 100% of individual
      fibroid volume.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Occurrence of Chronic Leg Pain</measure>
    <time_frame>From treatment to 1-month post-treatment</time_frame>
    <description>The hypothesis was that over 90% of subjects would not experience chronic leg pain. A lower 95% Confidence Limit &gt; 0.90 was considered statistically successful.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>ExAblate treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ExAblate</intervention_name>
    <description>Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation</description>
    <arm_group_label>ExAblate treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women age 18 or older

          -  Symptomatic uterine fibroids, defined as those resulting in scores of 21 or higher,
             based on patient responses to questions 1-8 of the Uterine Fibroid Symptom and
             Health-Related Quality of Life Questionnaire (UFS-QOL)

          -  Women who have given written informed consent

          -  Women who are able and willing to attend all study visits.

          -  Patient is pre or peri-menopausal (within 12 months of last menstrual period).

          -  Patient should be family complete.

          -  Able to communicate sensations during the ExAblate procedure.

          -  Uterine fibroids, which are device accessible (i.e., positioned in the uterus such
             that they can be accessed without being shielded by bowel or bone).

          -  Fibroids(s) clearly visible on non-contrast MRI.

          -  Fibroid enhances on MR contrast imaging.

        Exclusion Criteria:

          -  Women who are pregnant, as confirmed by serum/urine test at time of screening, or
             urine pregnancy test on the day of treatment.

          -  Patients who are breast-feeding.

          -  Patients with active pelvic inflammatory disease (PID).

          -  Patients with active local or systemic infection.

          -  Patients experiencing chronic leg or lower back pain within the last 6 months.

          -  Contraindication for MRI Scan:

               -  Severe claustrophobia that would prevent completion of procedure in the MR unit

               -  Weight greater than 250 lbs (113Kg)

               -  Implanted ferromagnetic materials and/or devices contraindicated for MR scan

               -  Known intolerance to MRI contrast agent (e.g. Gadolinium or Magnevist)

               -  Any other contraindication for MRI Scan

          -  Extensive abdominal scarring in the beam path (that cannot be avoided by redirection
             of the beam).

          -  Dermoid cyst of the ovary anywhere in the treatment path.

          -  Known or suspected pelvic carcinoma or pre-malignant conditions, including sarcoma and
             adenomatous hyperplasia.

          -  Intrauterine device (IUD) anywhere in the treatment path.

          -  Undiagnosed vaginal bleeding.

          -  Pedunculated fibroids.

          -  Uterine size &gt;24 weeks.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Department of Radiology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8749</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Image Guided Therapy</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Research Institute</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.insightec.com</url>
    <description>Sponsor's Web Page</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <results_first_submitted>January 4, 2019</results_first_submitted>
  <results_first_submitted_qc>March 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2019</results_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine fibroids</keyword>
  <keyword>MRgFUS</keyword>
  <keyword>ExAblate</keyword>
  <keyword>Focused Ultrasound</keyword>
  <keyword>Symptomatic uterine fibroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The protocol defined the primary analysis to include participants receiving more than 1 sonication, i.e., 115 in this case. The safety population was defined in the protocol as participants receiving any sonications which is 121. 6 subjects receiving only 1 sonication were in the safety population but not in the baseline or primary analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ExAblate Treatment</title>
          <description>ExAblate: Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation. Phase IV enhanced sonication technique.</description>
        </group>
        <group group_id="P2">
          <title>Additional Safety Population Particpants</title>
          <description>Per protocol 6 participants receiving only 1 sonication were added to the 115 ExAblate treated subjects to compose the full safety analysis population of 121. These 6 were included in adverse event reporting only, not in baseline or efficacy analyses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="6">6 participants receiving only 1 sonication were included only in adverse events reporting.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="6">Safety data only was reported for 6 participants receiving only 1 sonication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Alternative Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received only 1 sonication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline data is reported for the 115 participants who underwent the ExAblate treatment. Per protocol, 6 participants receiving only 1 sonication are included in the adverse events reporting only, not in the baseline or efficacy analyses..</population>
      <group_list>
        <group group_id="B1">
          <title>ExAblate Treatment</title>
          <description>ExAblate: Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>European/Middle East (White)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Occurrence of Chronic Leg Pain</title>
        <description>The hypothesis was that over 90% of subjects would not experience chronic leg pain. A lower 95% Confidence Limit &gt; 0.90 was considered statistically successful.</description>
        <time_frame>From treatment to 1-month post-treatment</time_frame>
        <population>Per protocol the number of participants analyzed was the number of participants receiving more than one sonication. Six subjects receiving one sonication were excluded from the primary analysis but included in the safety population for a safety sample size n = 121.</population>
        <group_list>
          <group group_id="O1">
            <title>ExAblate Treatment</title>
            <description>ExAblate: Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation. Phase IV enhanced sonication technique.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Occurrence of Chronic Leg Pain</title>
          <description>The hypothesis was that over 90% of subjects would not experience chronic leg pain. A lower 95% Confidence Limit &gt; 0.90 was considered statistically successful.</description>
          <population>Per protocol the number of participants analyzed was the number of participants receiving more than one sonication. Six subjects receiving one sonication were excluded from the primary analysis but included in the safety population for a safety sample size n = 121.</population>
          <units>percentage of subjects without leg pain</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 Month</time_frame>
      <desc>Per protocol a predetermined sample size of 115 participants receiving more than one sonication were included in the primary analysis. An additional 6 subjects receiving a single sonication were excluded from the primary analysis but included in the adverse events analysis for a safety sample size of 121.</desc>
      <group_list>
        <group group_id="E1">
          <title>ExAblate Treatment</title>
          <description>ExAblate: Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation. Phase IV enhanced sonication technique.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Bloating abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>GI upset</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cramping abdomen</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cramping back/buttock/leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Tenderness abdomen</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Flu</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mass - fat necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cramping position related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cramping muscle leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pain neck/shoulder position related</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pubic bone soreness position related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cramping muscle inguinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pain lower extremity position related</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Discomfort neck/shoulder position related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Tenderness abdomen position related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Parasthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Infection bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Edema/swelling abdome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Amennorhia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cramping menstrual</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Vaginal discharge/bleeding</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Infection IV site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Skin burn</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Skin pain sonication relaed</sub_title>
                <counts group_id="E1" events="67" subjects_affected="54" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cramping Sonication related</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pain uterine sonication related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Discomfort back/buttock/leg sonication related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pain abdomen sonication related</sub_title>
                <counts group_id="E1" events="78" subjects_affected="63" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pain back/buttock/leg sonication related</sub_title>
                <counts group_id="E1" events="104" subjects_affected="70" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Increased blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nadir Alikacem</name_or_title>
      <organization>InSightec</organization>
      <phone>214-630-2000</phone>
      <email>nadira@insightec.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

